G. Simons

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial

Deepak L. Bhatt, A. Verma, B. Zinman, 2019, Diabetes Care.

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes

W. Tamborlane, L. Laffel, J. George, 2018, Diabetes Care.

Rationale and design of the National Emphysema Treatment Trial (NETT): A prospective randomized trial of lung volume reduction surgery.

Sarah E. Duffy, D. Sugarbaker, S. Piantadosi, 1999, The Journal of thoracic and cardiovascular surgery.

Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial

W. Tamborlane, L. Laffel, S. Kaspers, 2018, Diabetic medicine : a journal of the British Diabetic Association.

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects

K. Dugi, G. Nehmiz, L. Seman, 2013, Clinical pharmacology in drug development.

The sodium glucose cotransporter 2 inhibitor empagliflozin does not prolong QT interval in a thorough QT (TQT) study

U. Broedl, H. Woerle, A. Ring, 2013, Cardiovascular Diabetology.